S. Ohmura

This study identifies how the EWS::FLI1-DHX9 interaction influences R-loop metabolism and Ewing sarcoma sensitivity to DNA topoisomerase 1 inhibitors.

This study identifies chr8 gains and 4E-BP1 expression as prognostic markers in Ewing sarcoma, showing they drive cancer progression by promoting proliferation and sensitizing to CDK4/6 inhibitors.

This paper develops a gene expression strategy that exploits neomorphic DNA-binding of fusion transcription factors in pediatric sarcomas to deliver therapeutic payloads with tumor-specific efficacy.

This study identifies RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma, showing its overexpression correlates with poor survival and that its inhibition reduces tumor growth and overcomes chemoresistance.

This study shows how a dominant oncogene and regulatory germline variants together influence tumor growth, survival, and drug response in Ewing sarcoma.

The paper identifies SOX6 as a therapeutic target in Ewing sarcoma by showing its role in elevating ROS levels, making the disease vulnerable to ROS-inducing drugs.

This study identifies subtype-specific prognostic biomarkers in prostate adenocarcinoma, showing that their prognostic value depends on TMPRSS2-ERG fusion status.

This study identifies CALCB as a direct EWSR1-FLI1 target in Ewing sarcoma and shows that targeting the CALCB/RAMP1-axis inhibits tumor growth.

This study identifies AMPD2 as a prognostic biomarker for undifferentiated pleomorphic sarcoma using transcriptome analysis, immunohistochemistry, and functional assays.

The paper introduces RAVEN, a software tool that identifies cancer-specific genes encoding MHC-affine peptides from gene expression data, validated across 50 cancer types.

This study identifies ATP1A1, BCL11B, and GLG1 as specific immunohistochemical markers for Ewing sarcoma, offering high specificity for diagnosis.